DNLI Similar Chart Price Prediction
The price of DNLI is predicted to go up 11.95%, based on the high correlation periods with ARMK. The similarity of these two price pattern on the periods is 93.01%.
DNLI
ARMK
Up: 11.95%Similarity: 93.01%
DNLI Revenue Forecast
DNLI EPS Forecast
DNLI FAQs
What is bull’s view on DNLI?
What is bear's view on DNLI?
What is DNLI eps forecast for next quarter？
DNLI Analyst's Forecast
Joel Beatty
Baird
Buy
2025-01-07
Price Target
$31
Upside
+46.36%
Baird last night initiated coverage of Denali Therapeutics with an Outperform rating and $31 price target. The firm believes Denali is likely to establish itself as a commercial company in late 2025 or early 2026, with an accelerated approval by the FDA of lead agent tividenofusp alfa, an enzyme replacement therapy for Hunter syndrome. Due to its brain penetration, DNL310 should quickly take a significant market share from Elaprase's $700M annual sales, the analyst tells investors in a research note. Baird also views Denali 's preclinical "Peak 2" programs targeting Alzheimer's disease and Parkinson's disease as attractive longer-term opportunities.
Sarah Schram
William Blair
Buy
2025-01-03
Price Target
n/a
Downside
0%
Michael Yee
Jefferies
Strong Buy
2024-11-01
Price Target
$40 → $45
Upside
+66.36%
